August 24, 2020Clinical Infectious Diseases

First Real-world Evidence of Meningococcal Group B Vaccine, 4CMenB, Protection Against Meningococcal Group W Disease: Prospective Enhanced National Surveillance, England

View Full Paper

Ask AI

Bookmark

Abstract

This is the first real-world evidence of direct protection afforded by 4CMenB against MenW:cc11 disease. 4CMenB has the potential to provide some protection against all meningococcal serogroups.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ladhani et al. (2020) studied this question.

synapsesocial.com/papers/69df19aad5404a0bea591ec1 https://doi.org/10.1093/cid/ciaa1244

View Full Paper

Ask AI

Bookmark

Abstract

This is the first real-world evidence of direct protection afforded by 4CMenB against MenW:cc11 disease. 4CMenB has the potential to provide some protection against all meningococcal serogroups.